Company intelligence / Profile preview
Valitor
Berkeley, California, United Statesvalitorbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Preclinical data for VLTR-557 (anti-VEGF antibody conjugate) shows >1,000-fold increases in VEGF binding affinity, up to 10-fold increases in tissue retention, and excellent preclinical safety. The data supports twice-yearly dosing potential for wet AMD.
- Therapeutic areas
- Ophthalmology
- Modalities
- Protein-based drugsantibody conjugatesmultivalent biopolymers
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Valitor.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Valitor.